A randomised phase III study of radiation doses and fractionation schedules for non-low risk ductal carcinoma in situ of the breast

非低风险乳腺导管原位癌放射剂量和分割方案的随机 III 期研究

• 批准号: nhmrc : 1099860
• 负责人: Dr A.Helen Westenberg
• 金额: $ 45.29万
• 依托单位: The University of New South Wales
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2016
• 资助国家: 澳大利亚
• 起止时间: 2016-01-01 至 2020-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/randomised-phase-iii-situ-breast/662475
• 关键词: randomised; phase; III; study; radiation

After surgery to remove ductal carcinoma in situ (DCIS), a pre-invasive form of breast cancer, radiotherapy to the breast decreases the risk of recurrence. The study investigates if a higher radiation dose to the tumour bed improves tumour control, and if a shorter course of radiotherapy is as effective as the standard longer course. It also assesses quality of life consequences of treatment and tests biomarkers that may predict the risk of recurrence in individual patients.

在手术切除乳腺导管原位癌（DCIS）（一种浸润前乳腺癌）后，对乳房进行放射治疗可降低复发风险。该研究调查了对肿瘤床的较高辐射剂量是否可以改善肿瘤控制，以及较短疗程的放射治疗是否与标准的较长疗程一样有效。它还评估治疗的生活质量后果，并测试可能预测个体患者复发风险的生物标志物。